Logo Logo
Eine Ebene nach oben
Exportieren als [RSS feed] RSS 1.0 [RSS2 feed] RSS 2.0
Gruppiert nach: Dokumententyp | Veröffentlichungsdatum
Anzahl der Publikationen: 15

Zeitschriftenartikel

Fischer, Laura E. ORCID logoORCID: https://orcid.org/0000-0001-8752-5827; Stintzing, Sebastian; Weikersthal, Ludwig Fischer von; Modest, Dominik P.; Decker, Thomas; Kiani, Alexander ORCID logoORCID: https://orcid.org/0000-0002-2494-4087; Kaiser, Florian; Al-Batran, Salah-Eddin; Heintges, Tobias; Lerchenmüller, Christian; Kahl, Christoph; Seipelt, Gernot; Kullmann, Frank; Stauch, Martina; Scheithauer, Werner; Giessen-Jung, Clemens; Uhlig, Jens; Peuser, Bettina; Denzlinger, Claudio; Stahler, Arndt; Weiss, Lena; Heinrich, Kathrin; Held, Swantje; Jung, Andreas; Kirchner, Thomas und Heinemann, Volker (2022): Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3. In: British Journal of Cancer, Bd. 127, Nr. 5: S. 836-843 [PDF, 788kB]

Heinrich, Kathrin; Modest, Dominik P.; Ricard, Ingrid; Fischer von Weikersthal, Ludwig; Decker, Thomas; Kaiser, Florian; Graeven, Ullrich; Uhlig, Jens; Schenk, Michael; Freiberg-Richter, Jens; Peuser, Bettina; Denzlinger, Claudio; Giessen-Jung, Clemens; Stahler, Arndt; Michl, Marlies; Held, Swantje; Jung, Andreas; Kirchner, Thomas; Stintzing, Sebastian und Heinemann, Volker (2021): Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study, AIO-KRK-0110). In: European Journal of Cancer, Bd. 147: S. 128-139

Kunzmann, Volker; Siveke, Jens T.; Alguel, Hana; Goekkurt, Eray; Siegler, Gabriele; Martens, Uwe; Waldschmidt, Dirk; Pelzer, Uwe; Fuchs, Martin; Kullmann, Frank; Boeck, Stefan; Ettrich, Thomas J.; Held, Swantje; Keller, Ralph; Klein, Ingo; Germer, Christoph-Thomas; Stein, Hubert; Friess, Helmut; Bahra, Marcus; Jakobs, Ralf; Hartlapp, Ingo und Heinemann, Volker (2021): Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. In: Lancet Gastroenterology & Hepatology, Bd. 6, Nr. 2: S. 128-138

Stahler, Arndt; Heinemann, Volker; Schuster, Veronika; Heinrich, Kathrin; Kurreck, Annika; Giessen-Jung, Clemens; Weikersthal, Ludwig Fischer von; Kaiser, Florian; Decker, Thomas; Held, Swantje; Graeven, Ullrich; Schwaner, Ingo; Denzlinger, Claudio; Schenk, Michael; Neumann, Jens; Kirchner, Thomas; Jung, Andreas; Kumbrink, Jorg; Stintzing, Sebastian und Modest, Dominik P. (2021): Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial). In: European Journal of Cancer, Bd. 157: S. 71-80

Kurreck, Annika; Heinemann, Volker; Fischer von Weikersthal, Ludwig; Decker, Thomas; Kaiser, Florian; Uhlig, Jens; Schenk, Michael; Freiberg-Richter, Jens; Peuser, Bettina; Denzlinger, Claudio; Graeven, Ullrich; Schwaner, Ingo; Stahler, Arndt; Heinrich, Kathrin; Jung, Andreas; Held, Swantje; von Einem, Jobst C.; Stintzing, Sebastian; Giessen-Jung, Clemens und Modest, Dominik P. (2020): Impact of age on efficacy and early mortality of initial sequential treatment versus upfront combination chemotherapy in patients with metastatic colorectal cancer: a subgroup analysis of a phase III trial (AIO KRK0110, XELAVIRI study). In: European Journal of Cancer, Bd. 137: S. 81-92

Heinemann, Volker; Fischer von Weikersthal, Ludwig; Decker, Thomas; Kiani, Alexander; Kaiser, Florian; Al-Batran, Salah-Edin; Heintges, Tobias; Lerchenmüller, Christoph; Kahl, Christoph; Seipelt, Gernot; Kullmann, Frank; Moehler, Markus; Scheithauer, Werner; Held, Swantje; Miller-Phillips, Lisa; Modest, Dominik Paul; Jung, Andreas; Kirchner, Thomas und Stintzing, Sebastian (2020): FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial. In: British Journal of Cancer, Bd. 124, Nr. 3: S. 587-594

Schulz, Christoph; Heinemann, Volker; Heinrich, Kathrin; Haas, Michael; Holch, Julian W.; Fraccaroli, Alessia; Held, Swantje; Einem, Jobst C.von; Modest, Dominik P.; Fischer von Weikersthal, Ludwig; Kullmann, Frank; Moehler, Markus; Scheithauer, Werner; Jung, Andreas und Stintzing, Sebastian (2020): Predictive and prognostic value of magnesium serum level in FOLFIRI plus cetuximab or bevacizumab treated patients with stage IV colorectal cancer: results from the FIRE-3 (AIO KRK-0306) study. In: Anti-Cancer Drugs, Bd. 31, Nr. 8: S. 856-865

Stahler, Arndt; Stintzing, Sebastian; Modest, Dominik P.; Ricard, Ingrid; Giessen-Jung, Clemens; Kapaun, Christine; Ivanova, Boryana; Kaiser, Florian; Fischer von Weikersthal, Ludwig; Moosmann, Nicolas; Schalhorn, Andreas; Stauch, Martina; Kiani, Alexander; Held, Swantje; Decker, Thomas; Moehler, Markus; Neumann, Jens; Kirchner, Thomas; Jung, Andreas und Heinemann, Volker (2020): Amphiregulin Expression Is a Predictive Biomarker for EGFR Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials. In: Clinical Cancer Research, Bd. 26, Nr. 24: S. 6559-6567

Modest, Dominik Paul; Heinemann, Volker; Folprecht, Gunnar; Denecke, Timm; Pratschke, Johann; Lang, Hauke; Bemelmans, Marc; Becker, Thomas; Rentsch, Markus; Seehofer, Daniel; Bruns, Christiane J.; Gebauer, Bernhard; Held, Swantje; Stahler, Arndt; Heinrich, Kathrin; Einem, Jobst C. von; Stintzing, Sebastian; Neumann, Ulf P. und Ricard, Ingrid (2020): Factors That Influence Conversion to Resectability and Survival After Resection of Metastases in RAS WT Metastatic Colorectal Cancer (mCRC): Analysis of FIRE-3-AIOKRK0306. In: Annals of Surgical Oncology, Bd. 27, Nr. 7: S. 2389-2401

Modest, Dominik P.; Martens, Uwe M.; Riera-Knorrenschild, Jörge; Greeve, Jobst; Florschuetz, Axel; Wessendorf, Swen; Ettrich, Thomas; Kanzler, Stephan; Noerenberg, Dominik; Ricke, Jens; Seidensticker, Max; Held, Swantje; Buechner-Steudel, Petra; Atzpodien, Jens; Heinemann, Volker; Seufferlein, Thomas; Tannapfel, Andrea; Reinacher-Schick, Anke C. und Geissler, Michael (2019): FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109). In: Journal of Clinical Oncology, Bd. 37, Nr. 35

Modest, Dominik Paul; Fischer von Weikersthal, Ludwig; Decker, Thomas; Vehling-Kaiser, Ursula; Uhlig, Jens; Schenk, Michael; Freiberg-Richter, Jens; Peuser, Bettina; Denzlinger, Claudio; Reddemann, Christina Peveling Genannt; Graeven, Ullrich; Schuch, Gunter; Schwaner, Ingo; Stahler, Arndt; Jung, Andreas; Kirchner, Thomas; Held, Swantje; Stintzing, Sebastian; Giessen-Jung, Clemens und Heinemann, Volker (2019): Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled StudyXELAVIRI (AIO KRK0110). In: Journal of Clinical Oncology, Bd. 37, Nr. 1

Modest, Dominik P.; Stintzing, Sebastian; Fischer von Weikersthal, Ludwig; Decker, Thomas; Kiani, Alexander; Vehling-Kaiser, Ursula; Al-Batran, Salah-Eddin; Heintges, Tobias; Lerchenmüller, Christian; Kahl, Christoph; Seipelt, Gernot; Kullmann, Frank; Scheithauer, Werner; Kirchner, Thomas; Jung, Andreas; Stauch, Martina; Einem, Jobst Christian von; Möhler, Markus; Held, Swantje und Heinemann, Volker (2017): Relation of early tumor shrinkage (ETS) observed in first-line treatment to efficacy parameters of subsequent treatment in FIRE-3 (AIOKRK0306). In: International Journal of Cancer, Bd. 140, Nr. 8: S. 1918-1925

Modest, Dominik Paul; Held, Swantje und Heinemann, Volker (2016): Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial Reply. In: Journal of Clinical Oncology, Bd. 34, Nr. 13: S. 1565-1566

Modest, Dominik Paul; Stintzing, Sebastian; Fischer von Weikersthal, Ludwig; Sobrero, Alberto F.; Decker, Thomas; Kiani, Alexander; Vehling-Kaiser, Ursula; Al-Batran, Salah-Eddin; Heintges, Tobias; Seipelt, Gernot; Lerchenmüller, Christian A.; Kahl, Christoph; Kullmann, Frank; Stauch, Martina; Scheithauer, Werner; Held, Swantje; Moehler, Markus H.; Jung, Andreas; Kirchner, Thomas und Heinemann, Volker (2016): Time-course evaluation of survival and treatment in FIRE-3 (AIO KRK0306, first-line therapy of KRAS wild-type metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab). In: Journal of Clinical Oncology, Bd. 34, Nr. 4

Stintzing, Sebastian; Modest, Dominik P.; Rossius, Lisa; Lerch, Markus M.; Fischer von Weikersthal, Ludwig; Decker, Thomas; Kiani, Alexander; Vehling-Kaiser, Ursula; Al-Batran, Salah-Eddin; Heintges, Tobias; Lerchenmüller, Christian; Kahl, Christoph; Seipelt, Gernot; Kullmann, Frank; Stauch, Martina; Scheithauer, Werner; Held, Swantje; Giessen-Jung, Clemens; Moehler, Markus; Jagenburg, Andreas; Kirchner, Thomas; Jung, Andreas und Heinemann, Volker (2016): FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. In: Lancet Oncology, Bd. 17, Nr. 10: S. 1426-1434

Diese Liste wurde am Sat Mar 23 21:06:00 2024 CET erstellt.